Biotech Startups

Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials. It serves chemists and drug discovery teams seeking to accelerate research through rapid, customizable synthesis planning.

2 investors

ILC Therapeutics is a biotechnology company developing hybrid interferon therapeutics, including its Alfacyte product, based on an interferon platform. The company operates in the drug development and pharmaceutical industry.

2 investors

Illimis Therapeutics is a biotech company developing therapeutics for intractable diseases, including GAIA-Aβ, a treatment aimed at improving Alzheimer's disease by clearing beta-amyloid via an efferocytosis-based mechanism that avoids the ARIA side effects of existing treatments. The company focuses on translating life science research into medicines for patients.

2 investors

Illume Labs aggregates data from wearables, blood tests, and genomic sequencing to deliver personalized health insights via text message and conversational AI, helping users understand changes in their health metrics and receive actionable recommendations.

2 investors

Illumi Medical is a medical device company based in Japan with research facilities in Nagoya and Koriyama. The page provides company contact and location information but does not specify the company's product offerings or business focus.

2 investors

Illumina Ventures is a venture capital firm focused on genomics and precision health, investing in early-stage companies developing breakthrough science and technology to improve human health. The firm provides capital, sequencing access, mentorship, and lab capabilities to portfolio companies through its Labs program.

2 investors

Imaginab develops advanced imaging solutions for immuno-oncology that visualize immune cell activity and treatment response without invasive biopsies. The company serves oncologists and clinical researchers seeking non-invasive alternatives for patient monitoring and treatment decision-making.

2 investors

Imel Biotherapeutics is a biotech company focused on mitochondrial biology, targeting mitochondrial dysfunction implicated in aging, cellular senescence, and T cell exhaustion in the elderly population.

2 investors

Immune Biosolutions provides GMP and non-GMP production facilities for the manufacturing and purification of recombinant antibodies and proteins. The company offers expression and purification services for both transient and stable cell-based systems, supporting preclinical and clinical development stages.

2 investors

Immuneel Therapeutics develops and manufactures cell-based immunotherapies, including CAR-T therapies, for cancer patients, with in-house cGMP lentiviral vector manufacturing. The company aims to make next-generation cell therapies affordable and accessible in India, with a global outlook.

2 investors

Immuneoncia develops immuno-oncology cancer therapeutics, including antibody drugs targeting PD-L1 and CD47, with a program targeting both CD47 and PD-L1 simultaneously. Based in South Korea, the company works to advance immune-based cancer treatments.

2 investors

IMMUNETHEP is a biotechnology company, spun off from the University of Porto, developing immunology-based technology originating from the Laboratory of Immunology of ICBAS. It conducts R&D from its facilities at Biocant Park in Cantanhede, Portugal.

2 investors

Immunito AI is an in-silico antibody discovery company that combines artificial intelligence with an in-house biological lab to speed up and improve the discovery of antibodies. It serves the biotech and biopharmaceutical industry.

2 investors

Immunity Project is a non-profit initiative developing an HIV vaccine aimed at curing HIV and AIDS. It intends to distribute the vaccine for free pending success in clinical trials.

2 investors

ImmunoBiome develops microbiome-based therapeutics targeting intractable immune diseases such as cancer and autoimmune disorders, drawing on immunology, bioinformatics, and microbiome research. The company operates in the biotech and drug development space.

2 investors

NapaJen Pharma is a biopharmaceutical research and development company developing nucleic acid (oligonucleotide) drugs using a proprietary cell-specific drug delivery platform that enables delivery to immune cells for precision-targeted immunosuppression and controlled immuno-stimulation. It develops its own drug candidates and partners with other pharmaceutical companies applying its delivery technology.

2 investors

Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.

2 investors

ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.

2 investors

Immuron is an Australian biopharmaceutical company developing and commercialising targeted polyclonal antibodies aimed at addressing unmet medical needs. Its products, based on a patented technology platform, are formulated to reduce diarrhoea, support gastrointestinal and digestive health, and promote immune defence.

2 investors

Immvention Therapeutics develops first-in-class BACH1 inhibitors intended as an oral therapy for patients with sickle cell disease and other conditions. The biotech company is working in collaboration with Novo Nordisk.

2 investors

ImpacFat develops stem-cell based omega-3 fish fat technology as a cultivated, sustainable alternative for the food industry. The Singapore-founded company works in the cultivated seafood and cellular agriculture space and is establishing an R&D hub in Tokyo, Japan.

2 investors

Impulse Dynamics develops implantable medical device technology for cardiac care, with a background in biomedical research and implantable cardiac electronics. The company operates in the cardiovascular medical device industry.

2 investors

ImYoo develops a platform that enables continuous, scalable biological data collection from patients outside traditional clinical settings to support precision medicine research and drug development. The platform addresses data gaps in healthcare by gathering longitudinal biological measurements from diverse patient populations to improve diagnostics, treatment matching, and clinical trial outcomes.

2 investors

In The Bowl Animal Health (ITBAH) develops and commercializes antiparasitics and therapeutics for pets by incorporating the drug directly into the pet's daily food to improve compliance and convenience. The company serves pet owners and veterinarians in the animal health market.

2 investors